Misuse of Drugs Act 1971

Part IIU.K. Class B Drugs

1U.K.The following substances and products, namely:—

[F1(a)]

  • Acetyldihydrocodeine.

  • Amphetamine.

  • [F2Cannabinol]

  • [F2Cannabinol derivatives]

  • [F2Cannabis and cannabis resin]

  • F3...

  • Codeine.

  • F4. . .

  • Dihydrocodeine.

  • Ethylmorphine (3-ethylmorphine).

  • [F5Glutethimide.]

  • [F5Lefetamine.]

  • [F6Mecloqualone.]

  • [F6Methaqualone.]

  • [F7Methcathinone]

  • F8...

  • F9...

  • [F10a-Methylphenethylhydroxylamine]

  • Methylphenidate.

  • [F6Methylphenobarbitone.]

  • Nicocodine.

  • [F11Nicodicodine (6-nicotinoyldihydrocodeine).]

  • Norcodeine.

  • [F12Pentazocine.]

  • Phenmetrazine.

  • Pholcodine.

  • [F13Propiram.]

  • [F7Zipeprol]

  • [F142-((Dimethylamino)methyl)-1-(3-hydroxyphenyl)cyclohexanol.]

[F15(aa)Any compound (not being bupropion, cathinone, diethylpropion, pyrovalerone or a compound for the time being specified in sub–paragraph (a) above) structurally derived from 2–amino–1–phenyl–1–propanone by modification in any of the following ways, that is to say,

(i)by substitution in the phenyl ring to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl or halide substituents, whether or not further substituted in the phenyl ring by one or more other univalent substituents;

(ii)by substitution at the 3–position with an alkyl substituent;

(iii)by substitution at the nitrogen atom with alkyl or dialkyl groups, or by inclusion of the nitrogen atom in a cyclic structure.]

[F16(ab)Any compound structurally derived from 2–aminopropan–1–one by substitution at the 1-position with any monocyclic, or fused‑polycyclic ring system (not being a phenyl ring or alkylenedioxyphenyl ring system), whether or not the compound is further modified in any of the following ways, that is to say,

(i)by substitution in the ring system to any extent with alkyl, alkoxy, haloalkyl or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents;

(ii)by substitution at the 3–position with an alkyl substituent;

(iii)by substitution at the 2‑amino nitrogen atom with alkyl or dialkyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure.]

[F17(ac)Any compound (not being pipradrol) structurally derived from piperidine, pyrrolidine, azepane, morpholine or pyridine by substitution at a ring carbon atom with a diphenylmethyl group, whether or not the compound is further modified in any of the following ways, that is to say,

(i)by substitution in any of the phenyl rings to any extent with alkyl, alkoxy, haloalkyl or halide groups;

(ii)by substitution at the methyl carbon atom with an alkyl, hydroxyalkyl or hydroxy group;

(iii)by substitution at the ring nitrogen atom with an alkyl, alkenyl, haloalkyl or hydroxyalkyl group.]

[F1(b)any 5,5 disubstituted barbituric acid.]

[F18(c)[2,3–Dihydro–5–methyl–3–(4–morpholinylmethyl)pyrrolo[1, 2, 3–de]–1,4–benzoxazin–6–yl]–1–naphthalenylmethanone.

  • [9–Hydroxy–6–methyl–3–[5–phenylpentan–2–yl] oxy–5, 6, 6a, 7, 8, 9, 10, 10a–octahydrophenanthridin–1–yl] acetate.

  • [9–Hydroxy–6–methyl–3–[5–phenylpentan–2–yl] oxy–5, 6, 6a, 7, 8, 9, 10, 10a–octahydrophenanthridin–1–yl] acetate.

  • 9-(Hydroxymethyl)–6, 6–dimethyl–3–(2–methyloctan–2–yl)–6a, 7, 10, 10a–tetrahydrobenzo[c]chromen–1–ol.

  • Any compound structurally derived from 3–(1–naphthoyl)indole, 3-(2-naphthoyl) indole, 1H–indol–3–yl–(1–naphthyl)methane or 1H-indol-3-yl-(2-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent.

  • Any compound structurally derived from 3–(1–naphthoyl)pyrrole or 3-(2-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent.

  • Any compound structurally derived from 1–(1–naphthylmethylene)indene or 1-(2-naphthylmethylene)indene by substitution at the 3–position of the indene ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent.

  • Nabilone.

  • Any compound structurally derived from 3–phenylacetylindole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent.

  • Any compound structurally derived from 2–(3–hydroxycyclohexyl)phenol by substitution at the 5–position of the phenolic ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the cyclohexyl ring to any extent.

  • Any compound structurally derived from 3-benzoylindole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent.

  • Any compound structurally derived from 3-(1-adamantoyl)indole or 3-(2-adamantoyl)indole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the adamantyl ring to any extent.

  • Any compound structurally derived from 3-(2,2,3,3-tetramethylcyclopropylcarbonyl)indole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent.

(d)1-Phenylcyclohexylamine or any compound (not being ketamine, tiletamine or a compound for the time being specified in paragraph 1(a) of Part 1 of this Schedule) structurally derived from 1-phenylcyclohexylamine or 2-amino-2-phenylcyclohexanone by modification in any of the following ways, that is to say,

(i)by substitution at the nitrogen atom to any extent by alkyl, alkenyl or hydroxyalkyl groups, or replacement of the amino group with a 1-piperidyl, 1-pyrrolidyl or 1-azepyl group, whether or not the nitrogen containing ring is further substituted by one or more alkyl groups;

(ii)by substitution in the phenyl ring to any extent by amino, alkyl, hydroxy, alkoxy or halide substituents, whether or not further substituted in the phenyl ring to any extent;

(iii)by substitution in the cyclohexyl or cyclohexanone ring by one or more alkyl substituents;

(iv)by replacement of the phenyl ring with a thienyl ring.]

Textual Amendments

F1Sch. 2 Pt. 2 para. 1(b) added by S.I. 1984/859, art. 2(3)

F2Words in Sch. 2 Pt. 2 para. 1(a) inserted (26.1.2009) by The Misuse of Drugs Act 1971 (Amendment) Order 2008 (S.I. 2008/3130), art. 2(2)(a)

F3Words in Sch. 2 Pt. 2 para. 1(a) deleted (29.1.2004) by The Misuse of Drugs Act 1971 (Modification) (No. 2) Order 2003 (S.I. 2003/3201), art. 2(3)

F4Word repealed by S.I. 1985/1995, art. 2(2)(a)

F5Word inserted by S.I. 1985/1995, art. 2(2)(b)

F6Word inserted by S.I. 1984/859, art. 2(3)

F7Words in Sch. 2 Pt. 2 para. 1(a) inserted (1.5.1998) by S.I. 1998/750, art. 2(3)

F8Word in Sch. 2 Pt. 2 para. 1(a) omitted (28.3.2011) by virtue of The Misuse of Drugs Act 1971 (Amendment) Order 2011 (S.I. 2011/744), arts. 1(1), 3

F9Word in Sch. 2 Pt. 2 para. 1(a) repealed (18.1.2007) by The Misuse of Drugs Act 1971 (Amendment) Order 2006 (S.I.2006/3331), art. 2(2)

F10Word in Sch. 2 Pt. 2 para. 1(a) inserted (1.2.2002) by S.I. 2001/3932, art. 2(3)

F11Words inserted by S.I. 1973/771, art. 2

F13Word inserted by S.I. 1973/771, art. 2

F14Words in Sch. 2 Pt. 2 para. 1(a) inserted (26.2.2013) by The Misuse of Drugs Act 1971 (Amendment) Order 2013 (S.I. 2013/239), art. 3

F15Sch. 2 Pt. 2 para. 1(aa) inserted (16.4.2010) by The Misuse of Drugs Act 1971 (Amendment) Order 2010 (S.I. 2010/1207), art. 2(b)

F17Sch. 2 Pt. 2 para. 1(ac) inserted (13.6.2012) by The Misuse of Drugs Act 1971 (Amendment) Order 2012 (S.I. 2012/1390), art. 2(a)

F18Sch. 2 Pt. 2 para. 1(c)(d) substituted (26.2.2013) for Sch. 2 Pt. 2 para. 1(c) by The Misuse of Drugs Act 1971 (Amendment) Order 2013 (S.I. 2013/239), art. 4

2U.K.Any stereoisomeric form of a substance for the time being specified in paragraph 1 of this Part of this Schedule.

[F192A.U.K.Any ester or ether of cannabinol or of a cannabinol derivative [F20or of a substance for the time being specified in [F21paragraph 1(ac), (c) or (d)] of this Part of this Schedule.] .]

Textual Amendments

F20Words in Sch. 2 Pt. 2 para. 2A inserted (23.12.2009) by Misuse of Drugs Act 1971 (Amendment) Order 2009 (S.I. 2009/3209), arts. 1, 2(2)(b)

F21Words in Sch. 2 Pt. 2 para. 2A substituted (26.2.2013) by The Misuse of Drugs Act 1971 (Amendment) Order 2013 (S.I. 2013/239), art. 5

3U.K.Any salt of a substance for the time being specified in paragraph 1 [F22, 2 or 2A] of this Part of this Schedule.

Textual Amendments

F22Words in Sch. 2 Pt. 2 para. 3 substituted ( 26.1.2009 ) by The Misuse of Drugs Act 1971 (Amendment) Order 2008 (S.I. 2008/3130), art. 2(2)(c)

4U.K.Any preparation or other product containing a substance or product for the time being specified in any of paragraphs 1 to 3 of this Part of this Schedule, not being a preparation falling within paragraph 6 of Part I of this Schedule.